Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Veracyte, Inc.'s quarterly P/E stands at 21.1x, down 87.2% year-over-year — suggesting improving earnings relative to price. EV/EBITDA has compressed 70.8% YoY to 20.9x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 44.23 | 21.05 | 35.76 | — | 84.23 | 165.00 | 44.79 | 77.39 | — | — | — | — | — |
| — | -87.2% | -20.2% | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 5.57 | 6.09 | 5.19 | 4.15 | 5.18 | 6.67 | 5.76 | 3.65 | 4.28 | 5.12 | 4.51 | 5.11 | 4.88 |
| — | -8.7% | -10.0% | +13.6% | +21.2% | +30.2% | +27.8% | -28.5% | -12.4% | -3.5% | +14.7% | +4.7% | -32.6% | |
| P/B Ratio | 2.23 | 2.62 | 2.18 | 1.77 | 1.99 | 2.69 | 2.27 | 1.48 | 1.48 | 1.93 | 1.54 | 1.70 | 1.49 |
| — | -2.8% | -4.2% | +19.8% | +34.1% | +39.7% | +47.3% | -13.4% | -0.5% | +21.5% | +35.9% | +27.6% | -17.7% | |
| P/FCF | 22.73 | 17.75 | 16.30 | 16.71 | 167.49 | 38.81 | 24.09 | 15.60 | — | 38.51 | 35.75 | 35.50 | — |
| — | -54.3% | -32.3% | +7.1% | — | +0.8% | -32.6% | -56.1% | — | -28.8% | -36.1% | — | — | |
| EV / EBITDA | 44.23 | 20.86 | 21.81 | 2252.24 | 67.69 | 71.34 | 33.76 | 35.21 | 391.20 | — | — | — | — |
| — | -70.8% | -35.4% | +6296.2% | -82.7% | — | — | — | — | — | — | — | — | |
| EV / EBIT | 44.23 | — | 32.57 | 398.20 | 480.68 | 216.08 | 35.86 | 49.48 | — | — | — | — | — |
| — | — | -9.2% | +704.8% | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Veracyte, Inc.'s operating margin was 26.4% in Q4 2025, up 9.0 pp QoQ and up 22.9 pp YoY. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 10.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 9.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.1% | 72.5% | 69.2% | 69.0% | 69.5% | 66.4% | 68.2% | 68.1% | 64.5% | 70.1% | 69.4% | 61.8% | 68.2% |
| — | +9.2% | +1.5% | +1.3% | +7.7% | -5.3% | -1.7% | +10.2% | -5.4% | +5.3% | +5.7% | -5.9% | +4.9% | |
| Operating Margin | 11.2% | 26.4% | 17.4% | -4.0% | 2.5% | 3.5% | 10.4% | 4.0% | -4.8% | -36.2% | -35.2% | -8.9% | -12.7% |
| — | +651.5% | +67.8% | -200.5% | +152.8% | +109.7% | +129.4% | +145.2% | +62.3% | -435.7% | -175.1% | +39.5% | +43.4% | |
| Net Margin | 12.8% | 29.3% | 14.5% | -0.8% | 6.2% | 4.3% | 13.1% | 5.0% | -1.9% | -28.8% | -32.9% | -9.3% | -9.8% |
| — | +578.9% | +10.9% | -115.0% | +419.8% | +115.0% | +139.8% | +153.9% | +80.4% | -501.9% | -184.8% | +28.9% | +54.0% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 5.3% | 3.2% | 1.5% | -0.1% | 0.6% | 0.4% | 1.3% | 0.5% | -0.2% | -2.7% | -2.8% | -0.8% | -0.8% |
| — | +637.3% | +17.6% | -115.9% | +444.8% | +116.1% | +147.4% | +165.6% | +77.0% | -644.8% | -235.7% | +12.5% | +43.4% | |
| ROA | 4.9% | 3.0% | 1.4% | -0.1% | 0.5% | 0.4% | 1.2% | 0.5% | -0.2% | -2.5% | -2.6% | -0.7% | -0.7% |
| — | +647.2% | +16.8% | -115.6% | +434.7% | +115.7% | +146.6% | +165.0% | +77.0% | -650.1% | -237.2% | +11.9% | +42.9% | |
| ROIC | 4.4% | 2.8% | 1.7% | -0.4% | 0.2% | 0.3% | 1.0% | 0.4% | -0.4% | -3.1% | -2.7% | -0.7% | -0.8% |
| — | +763.8% | +72.6% | -199.7% | +153.7% | +110.5% | +136.5% | +156.7% | +53.4% | -603.0% | -237.4% | +23.2% | +30.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Veracyte, Inc.'s Debt/EBITDA ratio is 1.1x, down from 1.4x last quarter — comfortably within a safe range. The current ratio has improved 72.1% YoY to 8.15x, strengthening the short-term liquidity position. Debt/Equity has declined for 3 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | -29.8% | +92.1% | +126.5% | +236.7% | +256.7% | +28.6% | +33.4% | -1.6% | -11.6% | -18.1% | -17.0% | -24.9% | |
| Debt / EBITDA | 0.69 | 1.07 | 1.43 | 229.17 | 6.11 | 4.87 | 1.10 | 2.00 | 15.03 | — | — | — | — |
| — | -78.1% | +30.3% | +11330.7% | -59.4% | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.15 | 8.15 | 6.23 | 5.43 | 5.10 | 4.73 | 5.08 | 4.44 | 5.00 | 4.66 | 4.74 | 4.46 | 4.49 |
| — | +72.1% | +22.7% | +22.2% | +1.9% | +1.5% | +7.2% | -0.5% | +11.4% | +17.5% | +15.9% | +12.7% | +17.8% | |
| Quick Ratio | 7.81 | 7.81 | 5.94 | 5.10 | 4.78 | 4.46 | 4.79 | 4.17 | 4.69 | 4.40 | 4.46 | 4.26 | 4.25 |
| — | +75.1% | +24.2% | +22.2% | +1.9% | +1.3% | +7.3% | -2.1% | +10.2% | +17.6% | +15.8% | +14.8% | +17.7% | |
| Interest Coverage | — | — | — | — | — | — | 12017.00 | 4606.00 | — | -17753.50 | -15869.50 | -2683.67 | -1499.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonVeracyte, Inc.'s current P/E is 44.2x. The average P/E over the last 3 quarters is 47.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Veracyte, Inc.'s current operating margin is 11.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Veracyte, Inc.'s business trajectory between earnings reports.